Oral management in a male pediatric patient with Doose Syndrome. Case Report
DOI:
https://doi.org/10.56294/saludcyt20251697Keywords:
Pediatric dentistry, Neurology, Seizures, EpilepsyAbstract
Introduction: Doose syndrome, also known as myoclonus-astatic syndrome, is a rare form of epilepsy that usually presents in childhood and is characterized by myoclonic and drop or startled seizures, along with delayed psychomotor development. Dental management in patients with Doose syndrome requires a comprehensive approach, taking into account both the medical and psychological and social implications of the patient. This can influence the patient's ability to maintain postural stability, which could increase the risk of falls or accidents during dental treatment, as well as anticonvulsant treatment, which is common in these patients, since many of these drugs can have side effects related to oral health, such as xerostomia (dry mouth), which can predispose to dental caries and oral infections. Clinical Case: a four-year-old male patient, diagnosed with Doose syndrome, presents to the pediatric dentist's office with the purpose of receiving dental treatment and rehabilitation. The patient was seen after being previously referred to a neurology specialist, and a comprehensive treatment plan encompassing various strategies was implemented. This approach consisted of performing necessary surgical procedures and providing continuous follow-up for a period of 12 months, taking into account both his physical health and his psychological and social status. Thanks to this collaborative effort, the factors that could trigger seizure episodes were significantly reduced. As a result, a notable decrease in plaque accumulation was observed, the patient's oral cavity remained caries-free, and he better adapted to dental visits. Conclusion: the patient's rehabilitation was successful without any complications throughout the process. The procedure related to his management was subjected to further analysis, in which behavioral control measures were implemented, and was performed under local anesthesia. A notable improvement in both the patient's oral and general health was observed, evidenced by the increase in his weight and height during the follow-up visit, which took place six months after the initial evaluation.
References
1. Moraleda Sepúlveda E, López Resa P. Evaluating quality of life in families with Williams Syndrome patients. Health Qual Life Outcomes. 2021 Dec 1;19(1).
2. Hinokuma N, Nakashima M, Asai H, Nakamura K, Akaboshi S, Fukuoka M, et al. Clinical and genetic characteristics of patients with Doose syndrome. Epilepsia Open. 2020 Sep 1;5(3):442–50.
3. Oguni H. Epilepsy with myoclonic-atonic seizures, also known as Doose syndrome: Modification of the diagnostic criteria. European Journal of Paediatric Neurology [Internet]. 2022 Jan 1;36:37–50. Available from: https://doi.org/10.1016/j.ejpn.2021.11.009
4. Garrez I, Teuwen DE, Sebera F, Mutungirehe S, Ndayisenga A, Kajeneza D, et al. Very high epilepsy prevalence in rural Southern Rwanda: The underestimated burden of epilepsy in sub-Saharan Africa. Tropical Medicine and International Health. 2024 Mar 1;29(3):214–25.
5. Joshi C, Nickels K, Demarest S, Eltze C, Cross JH, Wirrell E. Results of an international Delphi consensus in epilepsy with myoclonic atonic seizures/ Doose syndrome. Seizure. 2021 Feb 1;85:12–8.
6. Frazão A, Santos S, Lebre P. Psychomotor Intervention Practices for Children with Autism Spectrum Disorder: a Scoping Review. Rev J Autism Dev Disord [Internet]. 2023;10(2):319–36. Available from: https://doi.org/10.1007/s40489-021-00295-2
7. Nickels K, Kossoff EH, Eschbach K, Joshi C. Epilepsy with myoclonic-atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort. Epilepsia [Internet]. 2021 Jan 1;62(1):120–7. Available from: https://doi.org/10.1111/epi.16752
8. Catron MA, Howe RK, Besing GLK, St. John EK, Potesta CV, Gallagher MJ, et al. Sleep slow-wave oscillations trigger seizures in a genetic epilepsy model of Dravet syndrome. Brain Commun. 2023;5(1).
9. Joshi NH, Deshpande AN, Deshpande NC, Rathore AS. Comparative evaluation of oral hygiene status and gingival enlargement among epileptic and healthy children as related to various antiepileptic drugs. J Indian Soc Periodontol. 2017 Mar 1;21(2):125–9.
10. Arevalo-Rodriguez I, Smailagic N, Roqué-Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A, et al. Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Vol. 2021, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2021.
11. Magsi R, Ryan C, Sheikh A, Noor M, Mahfooz N. Novel Gene Abnormality in Epilepsy with Myoclonic-Atonic Seizures (Doose Syndrome). Translation: The University of Toledo Journal of Medical Sciences. 2023 Jul 6;11(2).
12. Goyal A, Bhadravathi MC, Kumar A, Narang R, Gupta A, Singh H. Comparison of dental caries experience in children suffering from epilepsy with and without administration of long term liquid oral medication. Journal of Clinical and Diagnostic Research. 2016 Jun 1;10(6):ZC78–82.
13. Yeung PM, Wong VCN, McGrath CP, Yiu CKY, Lee GHM. Oral health status of children with epilepsy in Hong Kong. J Investig Clin Dent [Internet]. 2019 Nov 1;10(4):e12479. Available from: https://doi.org/10.1111/jicd.12479
14. Sanchez-Gutierrez T, Mengoni S, Sofologi M, Serrat E, Costanzo F. Parental perspectives on the quality of life of children with Down syndrome. Frontiers inPsychiatry. 2022;
15. Bankole NDA, Dokponou YCH, De Koning R, Dalle DU, Kesici Ö, Egu C, et al. Epilepsy care and outcome in low- and middle-income countries: A scoping review. J Neurosci Rural Pract. 2024;15(1):8–15.
16. Gidal BE. Drug absorption in the elderly: Biopharmaceutical considerations for the antiepileptic drugs. In: Epilepsy Research. Elsevier; 2006. p. 65–9.
17. Gidal BE. Drug absorption in the elderly: Biopharmaceutical considerations for the antiepileptic drugs. In: Epilepsy Research. Elsevier; 2006. p. 65–9.
18. Fazal Ghafoor PA, Rafeeq M, Dubey A. Original Research Oral finding in epileptic children…Ghafoor PA et al. Journal of International Oral Health. 2014;6(2):126–8.
19. Lundstrom A, Eeg-Olofsson O, Hamp SE. Effects of anti-epileptic drug treatment with carbamazepine or phenytoin on the oral state of children and adolescents. J Clin Periodontol. 1982;9:482–8.
20. Sharma A, Mathur VP. Refractory epilepsy and the ketogenic diet: Pathophysiological aspects and possible implications in dental practice. Journal of Indian Society of Pedodontics and Preventive Dentistry. 2011 Jul;29(3):188–92.
21. Alberto Verrotti E, Coppola G, Operto F, Fortunato D, Della Corte R, Verrotti A, et al. “Treatment of Severe Epileptic Syndromes” ‘Ketogenic diet and epilepsy: an up-date review’ Ketogenic diet and epilepsy: an up-date review. Journal of Pediatric Sciences. 2009;1(12).
22. Weijenberg A, van Rijn M, Callenbach PMC, de Koning TJ, Brouwer OF. Ketogenic Diet in Refractory Childhood Epilepsy. Child Neurol Open. 2018 Jan 1;5:2329048X1877949.
Published
Issue
Section
License
Copyright (c) 2025 Paola Natali Paredes Chinizaca, Raciel Jorge Sánchez Sánchez, Silvia Verónica Vallejo Lara, David Carrillo, Olga Fuenmayor Vinueza (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
